Teradyne rises 3.9% as UBS lifts target and bullish AI-related test demand backdrop persists

Teradyne (TER) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a fresh bullish sell-side note, with UBS raising its price target while reiterating a Buy stance. The stock has also been trading with momentum off its recent results and outlook, which highlighted strong demand trends linked to AI-driven semiconductor test spending.

Details:

UBS raised its price target on Teradyne to $200 from $165 and maintained a Buy rating, pointing to signs of demand “pull-ins” that may be related to custom ASIC and networking programs.

In its most recent quarterly update, Teradyne provided Q1 2026 guidance for revenue of $1.15B–$1.25B and non-GAAP EPS of $1.89–$2.25, reinforcing expectations for strong near-term growth.

Teradyne’s latest outlook and commentary have kept investor focus on AI-related compute test demand as a key driver for 2026 growth, which can amplify reactions to positive analyst actions.

This could also be helped by positioning ahead of upcoming industry events where the company plans to participate, which sometimes supports sentiment even without a specific new product announcement.

Sources:

TipRanks, Teradyne Investor Relations, Teradyne

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TER Insider Trading Activity

$TER insiders have traded $TER stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $TER stock by insiders over the last 6 months:

MERCEDES JOHNSON has made 0 purchases and 6 sales selling 3,750 shares for an estimated $814,362.
GREGORY STEPHEN SMITH (President and CEO) has made 0 purchases and 4 sales selling 3,878 shares for an estimated $653,659.
REGAN MILLS (President, Product Test) sold 788 shares for an estimated $262,301

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TER Hedge Fund Activity

We have seen 555 institutional investors add shares of $TER stock to their portfolio, and 449 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,142,744 shares (-72.5%) from their portfolio in Q4 2025, for an estimated $801,869,528
WELLINGTON MANAGEMENT GROUP LLP removed 1,971,740 shares (-96.8%) from their portfolio in Q4 2025, for an estimated $381,649,994
PRIMECAP MANAGEMENT CO/CA/ removed 1,834,698 shares (-71.9%) from their portfolio in Q4 2025, for an estimated $355,124,144
VAN ECK ASSOCIATES CORP removed 1,715,143 shares (-42.9%) from their portfolio in Q4 2025, for an estimated $331,983,079
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,482,272 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $286,908,568
POINT72 ASSET MANAGEMENT, L.P. removed 1,269,062 shares (-31.1%) from their portfolio in Q4 2025, for an estimated $245,639,640
JPMORGAN CHASE & CO removed 1,150,643 shares (-24.7%) from their portfolio in Q4 2025, for an estimated $222,718,459

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$TER Government Contracts

We have seen $10,425,139 of award payments to $TER over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

THIS REQUIREMENT IS FOR THE PROCUREMENT OF KITS, REQUIRED TO ASSEMBLE VDATS, IN ACCORDANCE WITH THE ATTACHE...: $4,374,363
ENHANCED POWER CONTROL ASSEMBLY TESTER (EPCAT): $1,585,760
DELIVERY ORDER 22: $859,264
ENHANCED POWER CONTROL ASSEMBLY TESTER (EPCAT): $288,962
SPECTRUM 9100 SUPPORT SVCS BASE YEAR: $235,081

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$TER Congressional Stock Trading

Members of Congress have traded $TER stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $TER stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$TER Analyst Ratings

Wall Street analysts have issued reports on $TER in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Cantor Fitzgerald issued a "Overweight" rating on 02/02/2026
Stifel issued a "Buy" rating on 01/30/2026
Citigroup issued a "Buy" rating on 11/12/2025
Goldman Sachs issued a "Sell" rating on 10/30/2025
UBS issued a "Buy" rating on 10/30/2025
Evercore ISI Group issued a "Outperform" rating on 10/30/2025
Susquehanna issued a "Positive" rating on 09/22/2025

To track analyst ratings and price targets for $TER, check out Quiver Quantitative's $TER forecast page.

$TER Price Targets

Multiple analysts have issued price targets for $TER recently. We have seen 10 analysts offer price targets for $TER in the last 6 months, with a median target of $287.5.

Here are some recent targets:

Atif Malik from Citigroup set a target price of $325.0 on 02/04/2026
James Schneider from Goldman Sachs set a target price of $300.0 on 02/04/2026
Mark Lipacis from Evercore ISI Group set a target price of $320.0 on 02/04/2026
C.J. Muse from Cantor Fitzgerald set a target price of $330.0 on 02/04/2026
Brian Chin from Stifel set a target price of $325.0 on 02/04/2026
Timothy Arcuri from UBS set a target price of $275.0 on 01/26/2026
Vivek Arya from B of A Securities set a target price of $260.0 on 01/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.